Screening for hepatic fibrosis in patients with psoriasis prescribed methotrexate: can we make a change?

Abstract

The aim of this study was to assess whether correlation existed between procollagen III N-terminal peptide levels, used in the monitoring for hepatic fibrosis in psoriasis patients prescribed methotrexate, and other screening tools (Fibrosis-4 score) and then resultant FibroScan®, with the aim of potentially altering current clinical practice. The retrospective analysis highlighted how both screening tools, if used, can prompt onward referral for FibroScan®, however the small sample size limited statistical conclusions. Nevertheless, we feel this observational study can help guide future investigation into potential changes to hepatic fibrosis monitoring for this cohort.